Tags (10) : pharmaceutical industry
ASEM Launches to Raise Awareness on Compounded GLP-1 Drug Safety
07/14/2026 | Companies
Americans for Safe and Effective Medicines,
ASEM,
clinical testing,
compounded GLP-1,
consumer awareness,
consumer survey,
counterfeit medicines,
drug compounding,
drug safety,
drug shortages,
FDA,
FDA approval,
FDA inspections,
GLP-1 medications,
GLP-1 therapy,
healthcare advocacy,
healthcare policy,
healthcare regulation,
healthcare transparency,
illegal compounding,
ingredient sourcing,
injectable medications,
mass compounding,
medical spas,
medication safety,
misleading marketing,
online pharmacies,
patient education,
patient safety,
pharmaceutical industry,
pharmaceutical regulation,
prescription drugs,
primary care physicians,
product recalls,
public health,
quality standards,
regulatory compliance,
state enforcement,
sterility concerns,
telehealth,
warning letters
Nuvation Bio's Taletrectinib Clears Key UK Regulatory Milestone for ROS1+ Lung Cancer
06/29/2026 | Companies
AACR Annual Meeting,
advanced lung cancer,
biotech,
cancer drug development,
cancer therapy,
cancer treatment advancements,
DOVBLERON,
Eisai,
Eisai partnership,
EMA,
European Medicines Agency,
FDA approval,
global healthcare,
IBTROZI,
International Recognition Procedure,
Journal of Clinical Oncology,
lung cancer research,
MAA,
Marketing Authorisation Application,
metastatic cancer treatment,
MHRA,
non-small cell lung cancer,
NSCLC treatment,
Nuvation Bio,
Nuvation Bio stock,
NYSE NUVB,
oncology,
oncology innovation,
pharmaceutical industry,
Phase 2 clinical trials,
precision medicine,
rare cancer mutations,
respiratory oncology,
ROS1-positive NSCLC,
ROS1+ lung cancer,
taletrectinib,
targeted therapy,
TRUST-I,
TRUST-II,
UK regulatory approval
Nippon Shinyaku and Boston Children's Hospital Partner on Neurology Research
06/23/2026 | Companies
biotech partnership,
Boston Children's Hospital,
Boston Children's Hospital collaboration,
Cambridge Massachusetts,
clinical research,
drug discovery,
healthcare industry,
healthcare innovation,
innovative therapies,
Kyoto Japan,
life sciences,
medical innovation,
medical research,
neurological disorders,
neurological therapeutics,
neurology research,
neuroscience,
Nippon Shinyaku,
Nippon Shinyaku research initiative,
NS Pharma,
NS Pharma IRP,
Paramus New Jersey,
pharmaceutical collaboration,
pharmaceutical industry,
rare disease research,
rare disease treatment,
research partnership,
Sponsored Research Agreement,
therapeutic development,
unmet medical needs
CordenPharma to Acquire AmbioPharm to Expand Peptide Manufacturing Platform
05/27/2026 | Companies
AmbioPharm,
API manufacturing,
Astorg,
biopharmaceuticals,
biotech industry,
BNP Paribas,
Carlyle Group,
CDMO,
China pharmaceutical manufacturing,
clinical peptide supply,
commercial peptide production,
contract development and manufacturing organization,
CordenPharma,
global peptide supply,
hybrid peptide synthesis,
LPPS,
North Augusta facility,
peptide API,
peptide APIs,
peptide commercialization,
peptide drug development,
peptide manufacturing,
peptide medicines,
peptide platform,
pharmaceutical acquisition,
pharmaceutical industry,
pharmaceutical manufacturing,
Shanghai manufacturing,
SPPS,
TAPS technology,
U.S. peptide manufacturing
FDA Modernization Act 2.0 and the Future of Non-Animal Models
05/04/2026 | Companies
2D cell cultures,
3D human biology,
96-well functional platforms,
automated hardware,
automated recording,
biotechnology,
cardiac research,
contractile force analysis,
drug development,
Duchenne muscular dystrophy,
electrophysiology,
FDA Modernization Act 2.0,
fluorescence readouts,
high-throughput screening,
human-relevant data,
life sciences webinar,
NAMs,
neuromuscular research,
neurotoxin potency testing,
Non-Animal Models,
optogenetics,
organ-on-a-chip,
pharmaceutical industry,
predictive modeling,
quantitative analysis,
regulatory science,
safety pharmacology,
skeletal muscle research,
toxicology research
Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
04/28/2026 | Companies
Abu Dhabi,
Alzheimer’s disease,
Arcera Life Sciences,
biologics,
biotechnology,
biotechnology incubation,
cardiometabolic diseases,
cell therapy,
China,
drug development,
emerging markets,
Fosun Pharma,
gene therapy,
global healthcare,
healthcare infrastructure,
innovation,
international collaboration,
joint ventures,
licensing,
life sciences,
market access,
memorandum of understanding,
Middle East healthcare,
MoU,
neurodegenerative diseases,
neuroscience,
oncology,
pharmaceutical industry,
R&D,
radiopharmaceuticals,
rare diseases,
research and development,
siRNA therapies,
small molecules,
strategic partnership,
UAE,
Vision 2030
Viatris’ Global Leadership in Advancing Access and Responsible Action Against AMR
11/20/2025 | Companies
AMR,
AMRIA,
antibiotic stewardship,
antibiotics access,
antimicrobial innovation,
antimicrobial resistance,
diagnostics access,
global collaboration,
global health,
healthcare policy,
pharmaceutical industry,
PLATINEA,
public health,
regulatory challenges,
responsible manufacturing,
sustainability,
UN Political Declaration on AMR,
Viatris
Leo’s 50-Year Journey at Viatris: Leadership, Innovation & Impact
02/19/2025 | Companies
career journey,
COVID-19,
employee appreciation,
future generations,
global health,
Great Place to Work,
high-quality medicines,
leadership,
Leo,
mentorship,
mergers,
Netherlands,
patient impact,
personal motivation,
pharmaceutical industry,
professional legacy,
strategic projects,
supply chain,
team collaboration,
Viatris,
workplace inclusivity
Enhancing Diversity in Clinical Trials: Why It Matters for Drug Development
01/15/2025 | Companies
clinical research,
clinical trial barriers,
clinical trial diversity,
clinical trial inclusion,
clinical trial participation,
clinical trial statistics,
clinical trials,
cultural competency,
diversity in clinical trials,
drug development,
ethnic diversity,
FDA guidelines,
health equity,
healthcare access,
healthcare disparities,
healthcare diversity,
medical research,
patient-centered development,
pharmaceutical industry,
Teva,
underrepresented groups
Schneider Electric Leads Decarbonization with Energize Program: Renewable Energy for Healthcare Supply Chain
09/27/2024 | Companies
Avantor,
climate action,
climate change,
corporate collaboration,
decarbonization,
Energize program,
energy management,
environmental impact,
healthcare emissions,
net-zero emissions,
pharmaceutical industry,
power purchase agreements,
renewable electricity procurement,
renewable energy,
Schneider Electric,
solar projects,
supply chain emissions,
sustainability,
Takeda Pharmaceuticals,
Teva Pharmaceuticals,
UCB
Most Popular Now
Environment News
Compliance
Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com


Companies